<DOC>
	<DOCNO>NCT02062281</DOCNO>
	<brief_summary>The 23-valent pneumococcal Polysaccharide vaccine ( 23vPPV ) develop child adult prevent pneumococcal disease pneumonia ( inflammation lung ) , meningitis ( inflammation brain lining ) , septicemia ( blood poisoning ) since 2006 China . Also , trivalent influenza vaccine ( TIV ) frequently administer child adult . The main objective study show vaccine safely administer together without affect immune response protect disease .</brief_summary>
	<brief_title>Study Evaluating Safety Immunogenicity 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine Children Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>1 . Generally healthy male female , adults 5065 year age , child 37 year age . 2 . Available duration trial approximately 2 month . 3 . No history severe adverse reaction associate vaccine . 1 . Subject medical history following : allergic history , allergic ingredient vaccine , egg , egg protein , etc . 2 . Serious adverse reaction vaccine anaphylaxis , hive , respiratory difficulty , angioedema , abdominal pain . 3 . Autoimmune disease immunodeficiency . 4 . Asthma unstable require emergent care , hospitalization intubation past two year require use oral intravenous corticosteroid . 5 . Diabetes mellitus ( type I II ) , exception gestational diabetes History thyroidectomy thyroid disease require medication within past 12 month . 6 . Serious angioedema episode within previous 3 year require medication previous two year . 7 . Bleeding disorder diagnose doctor ( e.g . factor deficiency , coagulopathy , platelet disorder require special precaution ) significant bruise bleed difficulty IM injection blood draw . 8 . Any history immunosuppressive medication cytotoxic medication inhale corticosteroid within past six month ( exception corticosteroid nasal spray allergic rhinitis topical corticosteroid acute uncomplicated dermatitis ) 9 . History blood product seasonal influenza vaccine administration within 3 month dose . 10 . Administration investigational research agent within 30 day dose . 11 . Administration live attenuate vaccine within 30 day dose Administration subunit inactivate vaccine , e.g. , pneumococcal vaccine , allergy treatment antigen injection , within 14 day dose . 12 . Axillary temperature &gt; 37.0 centigrade time dose . 13 . Psychiatric condition precludes compliance protocol . 14 . Any medical , psychiatric , social condition , occupational reason responsibility , judgment investigator , contraindication protocol participation impair volunteer 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>vaccine</keyword>
	<keyword>pneumococcal</keyword>
	<keyword>influenza</keyword>
</DOC>